Glutamate Ionotropic Kainate Receptors as Therapeutic Targets in Enzalutamide-Resistant and Neuroendocrine Prostate Cancer
Open Access
- 2 July 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (13) , 5945
Abstract
Treatment-induced neuroendocrine prostate cancer (t-NEPC) is the major form of resistance to androgen receptor signaling inhibitors (ARSI) in advanced prostate cancer, characterized by pronounced invasiveness and lineage plasticity. Through in-depth analysis of prostate cancer cohorts, we found that glutamate ionotropic receptor kainate (GRIK) family members, specifically GRIK2 and GRIK5, are highly expressed in neural lineage plastic prostate cancer cells, NEPC patient-derived xenografts (PDX), and NEPC patient samples. Their expression positively correlates with neuroendocrine markers and inversely correlates with androgen receptor (AR) activity. Additionally, functional analyses indicated that AR has a direct transcriptional inhibitory effect on GRIK2 and GRIK5, and the absence of AR signaling leads to the upregulation of GRIK2 and GRIK5. Further RNA sequencing analysis revealed that GRIK5 silencing reprograms the cellular transcriptome, resulting in significant downregulation of AR signaling and fatty acid metabolism, while simultaneously activating immune and inflammatory responses in enzalutamide-resistant prostate cancer cells. In both cell line and NEPC PDX organoid models, loss of GRIK5 impaired proliferation and clonogenic growth. Notably, GRIK5 also contributes to enzalutamide resistance. Pharmacological evaluation revealed that Pan-GRIK antagonists exhibit anti-tumor activity, although the required relatively high concentrations suggest that more potent therapeutic strategies should be developed. Collectively, this study establishes that GRIK family members play critical roles in enzalutamide resistance and NEPC progression, highlighting GRIK signaling as a potential therapeutic target for overcoming lineage plasticity in prostate cancer.Keywords
Funding Information
- National Institutes of Health (5R37CA249108-05)
- National Institutes of Health (5R01CA251253-05)
- National Institutes of Health (1R01CA308808-01)
- National Institutes of Health (2R21CA277171-03)
- U.S. Department of War (HT9425-23-1-0144)
- U.S. Department of War (HT9425-23-1-0325)
- U.S. Department of War (HT9425-23-1-0324)
This publication has 48 references indexed in Scilit:
- Peripheral Nerves in Cancer: Regulatory Roles and Therapeutic StrategiesMedcomm, 2026
- Advances in the treatment of malignant tumors with neurological drugsDiscover Oncology, 2025
- PROX1 drives neuroendocrine plasticity and liver metastases in prostate cancerCancer Letters, 2024
- AMPA receptor neurotransmission and therapeutic applications: A comprehensive review of their multifaceted modulationEuropean Journal of Medicinal Chemistry, 2024
- GRIK5 stimulates colon cancer growth and metastasis through cAMP/PKA/CADM3 signalingCell Biology International, 2023
- Neuropilin-2 axis in regulating secretory phenotype of neuroendocrine-like prostate cancer cells and its implication in therapy resistanceCell Reports, 2022
- Comprehensive analysis of the exocytosis pathway genes in cervical cancerThe American Journal of the Medical Sciences, 2022
- The structural arrangement and dynamics of the heteromeric GluK2/GluK5 kainate receptor as determined by smFRETBiochimica et Biophysica Acta (BBA) - Biomembranes, 2020
- Glutamate Ionotropic Receptor Kainate Type Subunit 3 (GRIK3) promotes epithelial‐mesenchymal transition in breast cancer cells by regulating SPDEF/CDH1 signalingMolecular Carcinogenesis, 2019
- Integrative Clinical Genomics of Advanced Prostate CancerCell, 2015